Detalhe da pesquisa
1.
HER2 missense mutations have distinct effects on oncogenic signaling and migration.
Proc Natl Acad Sci U S A
; 112(45): E6205-14, 2015 Nov 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-26508629
2.
HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor.
J Natl Compr Canc Netw
; 13(9): 1061-4, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-26358790
3.
The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.
Nat Commun
; 15(1): 1373, 2024 Feb 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-38355560
4.
The uncharted role of HER2 mutant alleles in breast cancer.
Oncotarget
; 14: 904-907, 2023 Oct 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-37921670
5.
Cellular FLICE-inhibitory protein (cFLIP) isoforms block CD95- and TRAIL death receptor-induced gene induction irrespective of processing of caspase-8 or cFLIP in the death-inducing signaling complex.
J Biol Chem
; 286(19): 16631-46, 2011 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-21454681
6.
Mechanisms of neratinib resistance in HER2-mutant metastatic breast cancer.
Cancer Drug Resist
; 5(4): 873-881, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36627899
7.
Poziotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer.
Cancer Res
; 82(16): 2928-2939, 2022 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35736563
8.
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer.
Nat Commun
; 12(1): 2940, 2021 05 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-34011995
9.
Thioredoxin reductase is a major regulator of metabolism in leukemia cells.
Oncogene
; 40(33): 5236-5246, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34239044
10.
Correction: Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression.
Oncogene
; 39(40): 6387-6392, 2020 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-32820250
11.
Epigenetic loss of AOX1 expression via EZH2 leads to metabolic deregulations and promotes bladder cancer progression.
Oncogene
; 39(40): 6265-6285, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31383940
12.
Retraction: Tobacco-specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer.
Cancer Prev Res (Phila)
; 17(6): 281, 2024 Jun 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38831722
13.
The prognostic effects of somatic mutations in ER-positive breast cancer.
Nat Commun
; 9(1): 3476, 2018 09 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30181556
14.
Author Correction: The prognostic effects of somatic mutations in ER-positive breast cancer.
Nat Commun
; 9(1): 4850, 2018 11 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-30429476
15.
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer.
Cell Rep
; 24(6): 1434-1444.e7, 2018 08 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30089255
16.
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer.
Cancer Discov
; 7(10): 1168-1183, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28801307
17.
Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder Cancer.
Cancer Prev Res (Phila)
; 10(10): 588-597, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28851690
18.
Proteogenomic integration reveals therapeutic targets in breast cancer xenografts.
Nat Commun
; 8: 14864, 2017 03 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-28348404
19.
HER2 activating mutations are targets for colorectal cancer treatment.
Cancer Discov
; 5(8): 832-41, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26243863
20.
Activating HER2 mutations in HER2 gene amplification negative breast cancer.
Cancer Discov
; 3(2): 224-37, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23220880